g plants and three research centers. In 2008, Chiesi achieved revenues of 748 million Euro (up 14.3% over 2007) and its investments in research totaled 108 million Euro, representing 14.4% of consolidated sales. Chiesi employs over 3,200 people, including over 300 in R&D. In addition, Chiesi maintains global alliances with some of the world's leading pharmaceutical companies, including Takeda Pharmaceuticals, Tanabe Seiyaku, 3M, Abbott, GSK, Novartis, Nycomed, and Pfizer.
Safe Harbor Statement
Statements in this press release regarding the proposed transaction between Chiesi and the Company; the benefits and synergies of the transaction; the progress and timing of our product development programs and related trials; our future opportunities; our strategy, future operations, financial position, future revenues and projected costs; our management's prospects, plans and objectives; and any other statements about management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including, without limitation, statements containing the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "should," "target," "will," "would," and similar expressions) should also be considered to be forward-looking statements.
There are a number of important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including the ability to consummate the transaction; the expected timeline for completing the transaction; our ability to develop and maintain the necessary sales, marketing, supply chain, distribution and manufacturing capabilities to commercialize our products, including difficulties relating to the manufacture of ZYFLO CR
Page: 1 2 3 4 5 6 7 8 Related medicine news :1
|SOURCE Cornerstone Therapeutics Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call2
. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development 3
. Cornerstone Therapeutics Announces New Board of Directors4
. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics5
. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team6
. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 257
. Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 20098
. Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel9
. Royer Animal Health Enters Into Exclusive Agreement With MWI Veterinary Supply for U.S. Distribution of Next-Generation Therapeutics to Treat Cancer and Infections10
. Prime Therapeutics Announces Departure of President and Chief Executive Officer Timothy Dickman11
. InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer